Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | PTPN7 | P35236 | 3/20 | 0.56 |
| ▸ | HMGCR | P04035 | 3/20 | 0.56 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 5/20 | 0.50 |
| ▸ | PPARD | Q03181 | 5/20 | 0.50 |
| ▸ | PPARA | Q07869 | 5/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16701316 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL970516 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL7382880 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL6539108 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL3980051 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL1702085 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL374773 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL1654498 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL1401237 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 | |
| SCHEMBL7292218 | 1.00 | TSHR (0.63) | TSHRLMNANFKB1PMP22HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541430-B2 | Peptides for use in treating obesity | NOVO NORDISK A/S (DK) | 2009-06-02 | — | — | US | claimed |
| US-20070244054-A1 | Peptides for use in treating obesity | NOVO NORDISK A/S (DK) | 2007-10-18 | — | — | US | claimed |
| EP-1625158-A2 | PEPTIDES FOR USE IN TREATING OBESITY | NOVO NORDISK A/S (DK) | 2006-02-15 | — | — | EP | claimed |
| WO-2004099246-A2 | PEPTIDES FOR USE IN TREATING OBESITY | NOVO NORDISK A/S (DK) | 2004-11-18 | — | — | WO | claimed |
| US-10023610-B2 | Ligands for prevention of neurotoxicity of the alzheimer's disease related amyloid-beta peptide | ALPHABETA AB (SE) | 2018-07-17 | — | — | US | disclosed |
| US-20160340387-A1 | NOVEL LIGANDS FOR PREVENTION OF NEUROTOXICITY OF THE ALZHEIMER'S DISEASE RELATED AMYLOID-BETA PEPTIDE | ALPHABETA AB (SE) | 2016-11-24 | — | — | US | disclosed |
| US-7541430-B2 | Peptides for use in treating obesity | NOVO NORDISK A/S (DK) | 2009-06-02 | — | — | US | disclosed |
| US-20090088388-A1 | Peptides for Use In Treating Obesity | NOVO NORDISK A/S (DK) | 2009-04-02 | — | — | US | disclosed |
| US-20080207493-A1 | Compounds for Use in the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2008-08-28 | — | — | US | disclosed |
| EP-1863841-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2007-12-12 | — | — | EP | disclosed |
| US-20070244054-A1 | Peptides for use in treating obesity | NOVO NORDISK A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| WO-2006097526-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-09-21 | — | — | WO | disclosed |
| EP-0464517-A2 | Amino acid derivatives with renin inhibiting activity | MERCK PATENT GmbH (DE) | 1992-01-08 | — | — | EP | disclosed |
| EP-0456039-A2 | Renin inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1991-11-13 | — | — | EP | disclosed |
| EP-0446485-A2 | Peptide analogues with renininhibiting activity | MERCK PATENT GmbH (DE) | 1991-09-18 | — | — | EP | disclosed |
| EP-0446751-A1 | Glycolic acid derivatives | MERCK PATENT GmbH (DE) | 1991-09-18 | — | — | EP | disclosed |
| EP-0418696-A2 | Derivatives of aminoacids | MERCK PATENT GmbH (DE) | 1991-03-27 | — | — | EP | disclosed |
| CN-1037155-A | Amino acid derivative | MERCK PATENT GMBH (DE) | 1989-11-15 | — | — | CN | disclosed |
| EP-0339483-A2 | Renin inhbiting amino-acid derivatives | MERCK PATENT GmbH (DE) | 1989-11-02 | — | — | EP | disclosed |
| EP-0337334-A2 | Renin-inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023610-B2 | Ligands for prevention of neurotoxicity of the alzheimer's disease related amyloid-beta peptide | APP, BACE1, PSEN1 | TSHR 2752/4885LMNA 1734/4885NFKB1 1928/4885 |
| US-20070244054-A1 | Peptides for use in treating obesity | NPY4R, GLP1R, NPY1R | TSHR 296/4885LMNA 3088/4885NFKB1 2722/4885 |
| US-20160340387-A1 | NOVEL LIGANDS FOR PREVENTION OF NEUROTOXICITY OF THE ALZHEIMER'S DISEASE RELATED AMYLOID-BETA PEPTIDE | APP, BACE1, PSEN1 | TSHR 2968/4885LMNA 2042/4885NFKB1 2030/4885 |
| US-20080207493-A1 | Compounds for Use in the Treatment of Obesity | MC4R, MC5R, MC3R | TSHR 146/4885LMNA 3946/4885NFKB1 2850/4885 |
| US-20090088388-A1 | Peptides for Use In Treating Obesity | NPY4R, GLP1R, NPY1R | TSHR 296/4885LMNA 3088/4885NFKB1 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.